产品
编 号：F746127
分子式：C22H19N3O2
分子量：357.41
分子式：C22H19N3O2
分子量：357.41
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 1613509-49-1
产品详情
生物活性：
SRI-41315 induces a prolonged pause at stop codons and suppresses PTCs (premature termination codons) associated with cystic fibrosis in immortalized and primary human bronchial epithelial cells, restoring CFTR (cystic fibrosis transmembrane conductance regulator) expression and function. SRI-41315 suppresses PTCs by reducing the abundance of the termination factor eRF1. SRI-41315 also potentiates aminoglycoside-mediated readthrough, leading to synergistic increases in CFTR activity.
体外研究：
SRI-41315 exhibits target cell cytotoxicity (CC50) values >50?μM in both FRT and 16BE14o- cells.SRI-41315 shows improved potency and efficacy in FRT cells that translated to 16HBE14o- cells.SRI-41315 (5 μM, 20 h) depletes eRF1 levels through a proteasome-mediated degradation pathway.
SRI-41315 induces a prolonged pause at stop codons and suppresses PTCs (premature termination codons) associated with cystic fibrosis in immortalized and primary human bronchial epithelial cells, restoring CFTR (cystic fibrosis transmembrane conductance regulator) expression and function. SRI-41315 suppresses PTCs by reducing the abundance of the termination factor eRF1. SRI-41315 also potentiates aminoglycoside-mediated readthrough, leading to synergistic increases in CFTR activity.
体外研究：
SRI-41315 exhibits target cell cytotoxicity (CC50) values >50?μM in both FRT and 16BE14o- cells.SRI-41315 shows improved potency and efficacy in FRT cells that translated to 16HBE14o- cells.SRI-41315 (5 μM, 20 h) depletes eRF1 levels through a proteasome-mediated degradation pathway.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备